MACROGENICS INC (MGNX)
Health Care · Biotechnology · NASDAQ
A clinical-stage biotechnology company leveraging proprietary bispecific DART technology and antibody-drug conjugates to develop novel cancer immunotherapies.
What MACROGENICS INC does
MacroGenics is a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer. The company utilizes proprietary technology platforms, including antibody-drug conjugates (ADCs) and multi-specific antibodies (DART and TRIDENT molecules), to advance a pipeline of oncology candidates. Following the 2026 divestiture of its manufacturing operations, MacroGenics operates with a lean, fully-outsourced model focused on R&D and pipeline advancement.
Recent developments
In July 2026, MacroGenics completed the sale of its GMP drug substance manufacturing operations to Bora Pharmaceuticals for $122.5 million, transitioning the company to a fully-outsourced manufacturing model. The company also implemented a workforce restructuring, resulting in a leaner organization of approximately 140 employees to focus on its clinical pipeline. Additionally, the FDA cleared the IND application for MGC030, with a Phase 1 study initiated in the third quarter of 2026.
From MACROGENICS INC's filing of 2026-08-14.
Themes: oncology, antibody-drug conjugates (ADCs), bispecific antibodies, immunotherapy, T-cell engagers, clinical-stage biotech
Fundamentals
- Price$3.55 as of 2026-10-08 close
- Market cap$226M as of 2026-08-08 (share count; price 2026-10-08)
- 1-year return+99.4% 2025-10-08 close $1.78 → 2026-10-08 close $3.55
- P/En/a negative earnings
- Net margin-49.9% FY2025, SEC XBRL
- ROE-134.2% FY2025, SEC XBRL
- Debt / equity3.24 as of 2026-09-03
- Revenue growth (YoY)+2.0% as of 2026-09-03
- Revenue CAGR (3y)-0.5% SEC XBRL
- Beta1.55 as of 2026-09-03
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How MGNX compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How MACROGENICS INC looks technically
MACROGENICS INC (MGNX) is trading 8.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 173 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 10, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago. It is 30.1% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 8.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +8.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.99 | $3.99 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.28 | $3.28 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 4.2. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 173 trading days ago — a "golden cross", a bullish long-term signal | 173 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 10, below the 25 that marks a real trend) | 10.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30) | 39.5 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($3.41 to $4.20) — its "stochastic" reading is 18 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 17.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 20 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $5.08 | $5.08 |
|---|---|---|
| From the 52-week high | it is 30.1% below its 52-week high (its highest price of the past year) | -30.1% |
| Above the 52-week low | it is 174.1% above its 52-week low (its lowest price of the past year) | +174.1% |
| Below the 52-week high | it is 30.1% below its highest point of the past year | 30.1% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $41.00 (set on 2014-02-03) | $41.00 |
| Given back of the 52-week move | over the past year its closes ranged ($1.33 to $4.86), and it has given back roughly a third of its rise from last year’s low — 37% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.57 to $2.68. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 37.1% |
| From the all-time high | it is 91.3% below its all-time high | -91.3% |
| Nearest price level | it is trading 4.9% above a support level at $3.38 — a price it turned at three times since 2025-01-24, most recently on 2026-07-24. Since 2024-10-08 it has 13 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.9% |
| All-time low | its lowest closing price on record is $0.99 (set on 2025-04-07) | $0.99 |
| Above the all-time low | it is 258.6% above its all-time low | +258.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 40th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2282 between its high and its low — about 6.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2282 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.44 and $4.32 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.44 – $3.88 – $4.32 |
| Typical daily range (% of price) | its price moves about 6.4% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.4% |
| Stretch from the 200-day average | it is trading 1.2 daily ranges above its 200-day average price (8.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.37× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.6% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.6% |
|---|---|---|
| Gap filled | a 2.5% gap down opened on 2026-09-08 has been "filled" 22 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 22 sessions ago |
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 18.9 percentage points (the stock lost 17.8% while the market gained 1.0%) | -18.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 27.6 percentage points (the stock lost 23.8% while the market gained 3.8%) | -27.6% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 5.8 percentage points (the stock gained 11.6% while the market gained 17.5%) | -5.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 84.5 percentage points (the stock gained 99.4% while the market gained 15.0%) | +84.5% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 6.2% of the share price. | -11.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 3% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $3.43 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | +3.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 11% below the average price paid since it last reported on 2026-08-13 (its 8-K), so the typical buyer over that stretch is under water. That average is $3.98 — a volume-weighted average of daily closes over 40 sessions, not a true tick-by-tick VWAP. | -10.9% |
Price levels it has turned at before
MGNX last closed at $3.55 on 2026-10-08. Since 2024-10-08 it has turned at 13 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.38 | Support | 4.9% below the last close | turned there three times · 2025-01-24 to 2026-07-24 |
| $3.79 | Resistance | 6.7% above the last close | turned there three times · 2024-12-02 to 2026-08-14 |
| $3.89 | Resistance | 9.6% above the last close | turned there three times · 2026-04-10 to 2026-09-10 |
| $2.93 | Support | 17.5% below the last close | turned there twice · 2025-01-21 to 2025-02-19 |
| $4.47 | Resistance | 26.0% above the last close | turned there twice · 2026-06-04 to 2026-09-04 |
| $2.16 | Support | 39.3% below the last close | turned there three times · 2025-03-04 to 2025-10-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $4.20.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 8 trading days, since 2026-09-29.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · trendless / choppy (low ADX) · lagging the market · Printed a doji candle | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.29 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$8.00 range $4.00 – $11.00; median $8.50
Analyst estimates, as of 2026-10-03. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MGNX
- Consensus EPS estimate-$0.1272 next reporting period, as of 2026-10-03
- Estimate change, 30 days+$0.1429 from -$0.27, on 2026-08-29, 35-day window
- Readings revised upward17% of 6 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical trial failure, delays, or safety events, including regulatory holds like the one on the LINNET study.","Uncertainty regarding the ability to raise additional capital or receive milestone payments from collaborations to sustain long-term operations.","Significant competition in the oncology space and the high costs associated with drug development."]
What changed in the latest 10-Q
AI-assisted comparison of MGNX's 10-Q filed 2026-05-13 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-13) identifies company as 'clinical-stage biopharmaceutical company' vs. older filing's 'biopharmaceutical company'
- Newer filing adds Note 12 reference regarding 'sale of the assets and liabilities related to our manufacturing operations'
- Newer filing adds statement about $60.0 million received from Sagard in May 2026
- Newer filing adds anticipated $122.5 million proceeds from sale of manufacturing operations to Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC
- Newer filing extends cash runway projection to 'through 2028' vs. older filing's 'into late 2027'
- Newer filing updates accumulated deficit reference point to March 31, 2026 with $1.3 billion amount vs. older filing's September 30, 2025 with $1.2 billion
- Newer filing changes manufacturing facility language from 'to support our clinical programs' to 'in our Maryland headquarters' and revises offset language from 'a portion' to 'a significant portion' of operating costs
- Removed:
- Older filing reference to '$50.0 million receivable from Sanofi' removed from newer filing
- Older filing's reference to Form 10-K 'for the fiscal year ended December 31, 2024' changed to '2025' in newer filing
- Older filing phrase 'We are currently advancing three proprietary product candidates' changed to 'We currently have three proprietary product candidates' in newer filing
- Older filing's 'multiple preclinical-stage programs' changed to 'preclinical-stage ADC and next generation T-cell engager programs' in newer filing
- Older filing listed products with registered trademark symbols (MARGENZA®, ZYNYZ®, TZIELD®) and different order; newer filing removes trademark symbols and reorders as ZYNYZ, MARGENZA, TZIELD
- Older filing reference to 'DART antibody targeting CD123' changed to 'DART molecule targeting CD123' in newer filing
- Older filing's 'two additional undisclosed pre-clinical development programs' changed to 'two additional undisclosed pre-clinical DART and TRIDENT molecule development programs' in newer filing
- Reworded:
- Period reference changed from 'September 30, 2025' to 'March 31, 2026' throughout the document
- Cash runway projection changed from 'combined with the $50.0 million receivable from Sanofi, plus projected' to 'combined with the $60.0 million received from Sagard in May 2026, and the anticipated $122.5 million proceeds...expected upon closing...from the sale of our manufacturing operations to Bora...as well as projected'
- Product description for ZYNYZ changed from 'ZYNYZ® (retifanlimab-dlwr)' listed third to 'ZYNYZ (retifanlimab-dlwr)' listed first
- Manufacturing description: 'to support our clinical programs. We also provide outsourced' changed to 'in our Maryland headquarters. We have utilized the facility to support our clinical programs and we also provide outsourced'
- Incyte milestone payments reference date changed from 'through September 30, 2025' to 'through March 31, 2026'
- Notes:
- The newer filing text appears truncated at the end of the Incyte section (cuts off mid-sentence), limiting full comparison of that section
- Older filing text also appears truncated at end of Collaborations section starting with 'Gilead', preventing complete comparison of that portion
Risk Factors
- Added:
- Added to risk factors (2026-05-13): 'our expectations regarding the closing of the sale of our CDMO Operations, including the timing of the closing and the anticipated upfront payment, as well as our expectations regarding the manufacturing supply agreement that we will enter into with the Purchaser prior to closing'
- Added to risk factors (2026-05-13): 'our ability to receive research funding and achieve anticipated milestones under our collaborations, as well as our ability to offset the operating costs of our manufacturing facility from our contract development and manufacturing services'
- Added to risk factors (2026-05-13): 'the potential benefits and future operation of our existing collaborations' (combined with another item in newer version)
- Removed:
- Removed from risk factors (2025-11-12): 'the anticipated receipt of sales milestone payments in connection with the sale of MARGENZA to TerSera Therapeutics, LLC (TerSera)'
- Removed from risk factors (2025-11-12): 'our ability to receive research funding and achieve anticipated milestones under our collaborations' (consolidated into longer statement in newer version)
- Reworded:
- Risk factors bullet point reorganized: 'our ability to receive research funding and achieve anticipated milestones under our collaborations' expanded to include 'as well as our ability to offset the operating costs of our manufacturing facility from our contract development and manufacturing services' (2026-05-13)
- New specific risk regarding CDMO Operations sale added with details about timing, upfront payment, and manufacturing supply agreement (2026-05-13 vs 2025-11-12)
- Notes:
- The two filings cover different reporting periods (March 31, 2026 vs. September 30, 2025), which may explain some operational changes reflected in risk factors
- Financial statement data is from different quarter-ends and comparison periods, making direct financial metric comparison less relevant to risk factor changes
- The older filing shows net income for Q3 2025 while newer filing shows net loss for Q1 2026, reflecting different operational periods
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 1 sell ($129086) — 1 selling insider
- Last 180 days · read to 2026-10-040 buys · 1 sell ($129086) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-19. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MGNX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding MGNX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 8,694,926
- Reported value $40,170,559
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about MGNX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
MGNX had 7,032,428 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
MGNX had 11.0% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 15.73 days to cover at the same settlement.
- Reported short interest (shares) 7,032,428
- Short interest (% of shares outstanding) 11.0%
- Prior settlement (shares) 7,124,937
- Reported change -1.3%
- Days to cover (reported) 15.73
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Seagen (Pfizer) (PFE)
- ImmunoGen (AbbVie) (ABBV)
- Amgen (AMGN)
- Regeneron (REGN)
- Bristol Myers Squibb (BMY)
- AstraZeneca (AZN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MGNX vs…
MACROGENICS INC is found in…
Frequently asked questions
What does MACROGENICS INC (MGNX) do?
MacroGenics is a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer. The company utilizes proprietary technology platforms, including antibody-drug conjugates (ADCs) and multi-specific antibodies (DART and TRIDENT molecules), to advance a pipeline of oncology candidates.
What sector is MACROGENICS INC (MGNX) in?
MACROGENICS INC (MGNX) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are MACROGENICS INC's (MGNX) competitors?
Notable peers of MACROGENICS INC (MGNX) include Seagen (Pfizer), ImmunoGen (AbbVie), Amgen, Regeneron and Bristol Myers Squibb. This peer set is informational only — not financial advice.
Is MACROGENICS INC (MGNX) overbought or oversold right now?
MACROGENICS INC (MGNX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 40, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MGNX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.